A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
Objective
To determine the effect on OS of adding GC4711 to SBRT compared to placebo in subjects with unresectable or borderline resectable nonmetastatic PC To evaluate the effects of adding GC4711 to SBRT on progression-free survival (PFS) locoregional control (LRC), and time to distant metastases (TDM) To evaluate the overall and in-field response following GC4711 + SBRT
